G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug - G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics Inc GTHX described safety data from the first 18 patients enrolled in its ongoing Phase 2 study of trilaciclib administered before sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Sacituzumab govitecan is marketed as trodelvy by Gilead Sciences Inc GILD.
"We believe we are seeing on-target effects of trilaciclib in the expected reduction in the rate of myelosuppression and the rates of diarrhea and potentially alopecia. We will continue to progress this trial and look forward to presenting a more comprehensive data set, including initial efficacy results, at a medical meeting in the second quarter of 2023," said Raj Malik, Chief Medical Officer at G1 Therapeutics.
Trilaciclib is well tolerated when administered before sacituzumab.
Initial data show a clinically meaningful on-target effect of trilaciclib to reduce (>50%) the rates of multiple adverse events compared to the previously published sacituzumab govitecan-hziy single-agent safety profile, including myelosuppression.
Price Action: GTHX shares are down 24.8% at $8.21 on the last check Wednesday.